Long-term leukemia-free survival after allogeneic marrow transplantation in patients with acute myelogenous leukemia

被引:0
|
作者
Greinix, HT
Keil, F
Brugger, SA
Reiter, E
Linkesch, W
Lechner, K
Schneider, B
Dieckmann, KU
Fischer, G
Schwarzinger, I
Haas, O
Hinterberger, W
Mannhalter, C
Geissler, K
Hocker, P
Jager, U
Kalhs, P
机构
[1] UNIV VIENNA,DEPT MED 1,DIV HEMATOL & HEMOSTASEOL,A-1090 VIENNA,AUSTRIA
[2] UNIV VIENNA,INST MED STAT & DOCUMENTAT,A-1090 VIENNA,AUSTRIA
[3] UNIV VIENNA,DEPT RADIOTHERAPY,A-1090 VIENNA,AUSTRIA
[4] UNIV VIENNA,DEPT BLOOD GRP SEROL & TRANSFUS MED,A-1090 VIENNA,AUSTRIA
[5] UNIV VIENNA,CLIN INST MED & CHEM LAB DIAGNOST,A-1090 VIENNA,AUSTRIA
[6] ST ANNA CHILDRENS HOSP,CHILDRENS CANC RES INST,A-1090 VIENNA,AUSTRIA
关键词
acute myelogenous leukemia; allogeneic marrow transplantation;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Between February 1982 and April 1995, 62 patients (37 male, 25 female) with acute myelogenous leukemia (AML) with a median age of 32 years (19-51 years) received allogeneic marrow grafts from an HLA-identical sibling (n = 60) or an HLA-mismatched family member (n = 2). At the time of transplant, 35 patients were in first complete remission (CR), five in second CR, eight were primary refractory, eight were in untreated relapse and six in refractory relapse. The FAB subtypes were as follows: M1 (n = 17), M2 (n = 13), M3 (n = 6), M4 (n = 19), M5 (n = 6), M6 (n = 1). For conditioning most patients were given total body irradiation combined with cyclophosphamide (CY, n = 50) or CY and busulfan (n = 9). For graft-versus-host disease prophylaxis patients received cyclosporin A (CSA) and methotrexate (MTX) (n = 32), MTX alone (n = 12), CSA and methylprednisone (n = 5), or CSA alone (n = 13). As of April 1995, probability of leukemia-free survival projected at 10 years after BMT was 60% for patients transplanted in first CR compared with 10% for patients transplanted beyond first CR. Transplant-related mortality was 11% after BMT in first CR and 39% after BMT beyond first CR. Probability of relapse projected at 10 years after BMT is 32% for patients who received transplants in first CR and 81% for patients who received transplants beyond first CR. Thus, high-dose chemo/radiotherapy followed by allogeneic marrow infusion has a high curative potential for patients with AML who receive transplants in first CR and offers the chance of long-term disease-free survival for some patients with advanced disease.
引用
收藏
页码:53 / 59
页数:7
相关论文
共 50 条
  • [1] Long term leukemia-free survival (LFS) after allogeneic stem cell transplantation in patients with chronic myelogenous leukemia
    Reiter, E
    Greinix, HT
    Schulenburg, A
    Keil, F
    Rabitsch, W
    Mannhalter, C
    Schwarzinger, I
    Fischer, G
    Leitner, G
    Dieckmann, K
    Schneider, B
    Lechner, K
    Kalhs, P
    [J]. BONE MARROW TRANSPLANTATION, 1998, 21 : S83 - S83
  • [2] FACTORS INFLUENCING LONG-TERM LEUKEMIA-FREE SURVIVAL AFTER ALLOGENEIC BONE-MARROW TRANSPLANTATION FOR ACUTE-LEUKEMIA
    ZWAAN, FE
    HERMANS, J
    LYKLEMA, A
    [J]. LEUKEMIA RESEARCH, 1986, 10 (01) : 92 - 92
  • [3] Factors impacting leukemia-free and overall survival of patients with acute myelogenous leukemia after allogeneic stem cell transplantation: report of the Austrian stem cell transplantation registry
    Greinix, HT
    Nachbaur, D
    Krieger, O
    Eibl, M
    Kalhs, P
    Lutz, D
    Linkesch, W
    Niederwieser, D
    Rosenmayr, A
    Gritsch, B
    [J]. BONE MARROW TRANSPLANTATION, 2001, 27 : S81 - S81
  • [4] Long-Term Outcomes After Transplantation for Acute Myelogenous Leukemia
    Socie, Gerard
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (28) : 3235 - +
  • [5] Long-term follow-up of allogeneic marrow transplantation for acute myelogenous leukemia after treatment with busulfan and cyclophosphamide
    Bolaños-Meade, J
    Hartley, E
    Jones, RJ
    [J]. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2006, 12 (03) : 366 - 367
  • [6] Diffusion capacity predicts long-term survival after allogeneic bone marrow transplantation for acute lymphoblastic leukemia
    Chang, Peter Mu-Hsin
    Chiou, Tzeon-Jye
    Yen, Chueh-Chuan
    Hsiao, Liang-Tsai
    Liu, Jin-Hwang
    Chen, Po-Min
    [J]. JOURNAL OF THE CHINESE MEDICAL ASSOCIATION, 2008, 71 (05) : 234 - 240
  • [7] COMPARABLE LONG-TERM LEUKEMIA-FREE SURVIVAL AFTER MATCHED SIBLING AND UNRELATED DONOR TRANSPLANTATION FOR CHILDREN WITH ACUTE LYMPHOBLASTIC LEUKEMIA IN SECOND COMPLETE REMISSION
    Thiel, E. L.
    Zhang, M. -J
    Davies, S. M.
    Kurtzberg, J.
    Logan, B.
    Ayas, M.
    MacMillian, M. L.
    Tiedemann, K.
    Eapen, M.
    [J]. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2010, 16 (02) : S267 - S267
  • [8] DISEASE-FREE SURVIVAL AFTER AUTOLOGOUS BONE-MARROW TRANSPLANTATION IN PATIENTS WITH ACUTE MYELOGENOUS LEUKEMIA
    KORBLING, M
    HUNSTEIN, W
    FLIEDNER, TM
    CAYEUX, S
    DORKEN, B
    FEHRENTZ, D
    HAAS, R
    HO, AD
    KEILHOLZ, U
    KNAUF, W
    KONIG, A
    MENDE, U
    PEZZUTTO, A
    VONREUMONT, J
    WOLF, GK
    WANNENMACHER, M
    ZUMWINKEL, K
    ROTHER, K
    [J]. BLOOD, 1989, 74 (06) : 1898 - 1904
  • [9] LONG-TERM LEUKEMIA-FREE SURVIVAL FOLLOWING RECURRENT CHILDHOOD LYMPHOCYTIC-LEUKEMIA (ALL)
    RIVERA, G
    AUR, RJ
    DAHL, GV
    HUSTU, HO
    SIMONE, JV
    [J]. PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1980, 21 (MAR): : 436 - 436
  • [10] Individualized prediction of leukemia-free survival after autologous stem cell transplantation in acute myeloid leukemia
    Shouval, Roni
    Labopin, Myriam
    Gorin, Norbert C.
    Bomze, David
    Houhou, Mohamed
    Blaise, Didier
    Zuckerman, Tsila
    Baerlocher, Gabriela M.
    Capria, Saveria
    Forcade, Edouard
    Huynh, Anne
    Saccardi, Riccardo
    Martino, Massimo
    Schaap, Michel
    Wu, Depei
    Mohty, Mohamad
    Nagler, Arnon
    [J]. CANCER, 2019, 125 (20) : 3566 - 3573